Last reviewed · How we verify
Mannitol-based 38% drug-loaded tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Mannitol-based 38% drug-loaded tablet (Mannitol-based 38% drug-loaded tablet) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mannitol-based 38% drug-loaded tablet TARGET | Mannitol-based 38% drug-loaded tablet | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mannitol-based 38% drug-loaded tablet CI watch — RSS
- Mannitol-based 38% drug-loaded tablet CI watch — Atom
- Mannitol-based 38% drug-loaded tablet CI watch — JSON
- Mannitol-based 38% drug-loaded tablet alone — RSS
Cite this brief
Drug Landscape (2026). Mannitol-based 38% drug-loaded tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/mannitol-based-38-drug-loaded-tablet. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing